Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

A Feasibility Study of Rapamycin with Hyper-CVAD Chemotherapy in Adults with Acute Lymphoblastic Leukemia (ALL) and Other Aggressive Lymphoid Malignancies and Evaluation of mTOR Signaling Using Phosphoflow

Emma C Scott, MD, Alexander Perl, MD, Selina M. Luger, MD, Martin Carroll, MD, Margaret Kasner, MD

Blood (2011) 118 (21): 4245.

https://doi.org/10.1182/blood.V118.21.4245.4245

Published: 2011

Journal Articles

Reduced Intensity Conditioning with Fludarabine/Busulfan 6.4mg/Kg Results In High Donor Chimerism and Low Toxicity In Both Related and Unrelated Allo-SCT for Hematologic Malignancies.

Steven C Goldstein, MD, Selina M. Luger, MD, Noelle Frey, MD, Alexander Perl, MD, Edward A Stadtmauer, MD, Donald Tsai, MD, Alison Loren, MD, Sunita Nasta, MD, Elizabeth Hexner, MD, Ran Reshef, MD, Jacqueline Smith, CRNP, Joanne Hinkle, Pavel Vassilev, BS, Michael J Vozniak, PharmD, David L. Porter, MD

Blood (2010) 116 (21): 4519.

https://doi.org/10.1182/blood.V116.21.4519.4519

Published: 2010

Journal Articles

Outcomes of Myeloablative Hematopoietic Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia with Relapsed or Refractory Disease

Courtney D. DiNardo, MD, Alison Loren, MD, Steven Goldstein, MD, Stephen J. Schuster, Alexander Perl, MD, Donald Tsai, MD, Noelle Frey, MD, Elizabeth Hexner, MD, Ran Reshef, MD, Edward A. Stadtmauer, MD, David L. Porter, MD, Selina Luger, MD

Blood (2010) 116 (21): 2366.

https://doi.org/10.1182/blood.V116.21.2366.2366

Published: 2010

Journal Articles

Combination Daclizumab and Infliximab for Steroid Refractory Acute Graft-Versus-Host Disease.

Alison Rager, MD, Steven C. Goldstein, MD, Noelle Frey, MD, Jennifer Davis, PharmD, Michael Vozniak, PharmD, Jacqueline Smith, Elizabeth Hexner, MD, Alison Wakoff Loren, MD, MS, Selina Luger, MD, Alexander Perl, MD, Ran Reshef, MD, Donald E Tsai, MD, PhD, Edward A. Stadtmauer, MD, David Porter, MD

Blood (2009) 114 (22): 4643.

https://doi.org/10.1182/blood.V114.22.4643.4643

Published: 2009

Journal Articles

First Report of the Prophylactic Administration of Ex Vivo Co-Stimulated Donor Lymphocyte Infusion (DLI) from Related and Unrelated Donors after Reduced Intensity Conditioning for High Risk Hematologic Malignancies

Steven C Goldstein, MD, Bruce Levine, PhD, Jacqueline Smith, MSN, CRNP, Joanne Hinkle, RN, BSN, OCN, Selina Luger, MD, Alexander Perl, MD, Alison Loren, MD, Noelle Frey, MD, Edward Stadtmauer, MD, Daniel Schullery, PhD, Jean Boyer, PhD, Dennis L. Confer, MD, David Porter, MD, Carl H. June, MD

Blood (2008) 112 (11): 468.

https://doi.org/10.1182/blood.V112.11.468.468

Published: 2008

Journal Articles

A Robust Xenotransplantation Model for Acute Myeloid Leukemia

Robin L. Perry, MD, Patricia Vanessa Sanchez, PHD, Jean-Emmanuel Sarry, PHD, Alexander Perl, MD, Adam Bagg, MD, Vivianna van Deerlin, Jacklyn Biegel, Gwenn-ael Danet-Desnoyers, Martin Carroll, MD

Blood (2008) 112 (11): 2939.

https://doi.org/10.1182/blood.V112.11.2939.2939

Published: 2008

Journal Articles

A Phase II Trial of Bexarotene, a Retinoid X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia

Donald E. Tsai, MD, PhD, Melissa Potuzak, BS, Anthony Mato, MD, Alison Wakoff Loren, MD, MS, David Porter, MD, Edward A. Stadtmauer, MD, Steven Goldstein, MD, Alexander Perl, MD, Cezary Swider, BS, Adam Bagg, MD, Emile Youssef, MD, PhD, Selina Luger, MD

Blood (2008) 112 (11): 4040.

https://doi.org/10.1182/blood.V112.11.4040.4040

Published: 2008

Journal Articles

Phosphoproteomic Analysis of Primary Acute Myeloid Leukemia Cells Reveals Redundant Roles for Src Family Kinases in AML Survival

Jamil K. Dierov, MD, PhD, DSc, Tae Kon Kim, Xiaowei Yang, Ph.D., Alexander Perl, MD, Beth A Burke, BS, Zhu Wang, Ting-Lei Gu, Alan M. Gewirtz, MD, Seth J. Corey, Roberto Polakiewicz, Ph.D., Martin Carroll, MD

Blood (2008) 112 (11): 2650.

https://doi.org/10.1182/blood.V112.11.2650.2650

Published: 2008

Journal Articles

A Phase I Trial of Bexarotene, a Retinoid X Receptor Agonist, in non-M3 Acute Myeloid Leukemia: Evidence of Myeloid Differentiation and Clinical Activity.

Donald E. Tsai, MD, PhD, Selina Luger, MD, Allison Kemner, RN, Alison W. Loren, MD, Cezary Swider, PhD, Ami Goradia, MD, Charalambos Andreadis, MD, Richard G. Ghalie, MD, James Thompson, MD, David Porter, MD, Edward A. Stadtmauer, MD, Stephen J. Schuster, MD, Alexander Perl, MD, Adam Bagg, MD, Steven Goldstein, MD, Martin Carroll, MD

Blood (2006) 108 (11): 1955.

https://doi.org/10.1182/blood.V108.11.1955.1955

Published: 2006

Journal Articles

A Randomized, Open-Label Study of Lestaurtinib (CEP-701), an Oral FLT3 Inhibitor, Administered in Sequence with Chemotherapy in Patients with Relapsed AML Harboring FLT3 Activating Mutations: Clinical Response Correlates with Successful FLT3 Inhibition.

Mark Levis, MD, PhD, B. Douglas Smith, MD, Miloslav Beran, MD, Maria R. Baer, MD, Harry P. Erba, MD, Larry Cripe, MD, Steven Coutre, MD, Anjali Advani, MD, Alexander Perl, MD, Marcel Devetten, MD, Robert Stuart, MD, Martin S. Tallman, MD, Peter Brown, PhD, Lothar Tremmel, Donald Small, MD, PhD

Blood (2005) 106 (11): 403.

https://doi.org/10.1182/blood.V106.11.403.403

Published: 2005

Journal Articles

Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy for Relapsed Multiple Myeloma.

Rebecca L. Olin, MD, David L. Porter, MD, Selina M. Luger, MD, Stephen J. Schuster, MD, Donald Tsai, MD, PhD, Sunita Nasta, MD, Alexander Perl, MD, Alison W. Loren, MD, Steven Goldstein, MD, Eli Glatstein, MD, Donald L. Siegel, MD, PhD, Dan T. Vogl, MD, Patricia Mangan, CRNP, Kathleen Cunningham, RN, BSN, Edward A. Stadtmauer, MD

Blood (2005) 106 (11): 1170.

https://doi.org/10.1182/blood.V106.11.1170.1170

Published: 2005

Journal Articles

Thalidomide and Dexamethasone Induction Therapy Is Associated with Superior Progression-Free Survival after Autotransplant for Myeloma.

Dan T. Vogl, MD, Selina Luger, MD, David L. Porter, MD, Elise A. Chong, Stephen J. Schuster, MD, Donald E. Tsai, MD, Alexander Perl, MD, Alison W. Loren, MD, MS, Stephen Goldstein, MD, Sunita D. Nasta, MD, Charalambos Andreadis, MD, Patricia A. Mangan, Kimberly Hummel, Donald L. Siegel, MD, PhD, Eli Glatstein, MD, Edward A. Stadtmauer, MD

Blood (2005) 106 (11): 1171.

https://doi.org/10.1182/blood.V106.11.1171.1171

Published: 2005

Journal Articles

Non-Myeloablative Conditioning with Allogeneic Progenitor Cell Transplantation for Relapsed Hodgkin’s Lymphoma: High Response Rate Despite Prior Chemoresistance.

Steven C. Goldstein, MD, Selina M. Luger, MD, Edward Stadtmauer, MD, Stephen Schuster, MD, Donald Tsai, MD, PhD, Sunita Nasta, MD, Alison Loren, MD, Alexander Perl, MD, Greg Orloff, MD, Julie Oliver, CRNP, Robert Sachs, Stephen Emerson, MD, PhD, David L. Porter, MD.

Blood (2004) 104 (11): 2258.

https://doi.org/10.1182/blood.V104.11.2258.2258

Published: 2004

Journal Articles

Utility of Prophylactic Autologous Stem Cell Collection for Patients with Acute Myeloid Leukemia in First Remission.

Margie Kasner, MD, Selina Luger, MD, Edward Stadtmauer, MD, Stephen Schuster, MD, Donald Tsai, MD, Sunita Nasta, MD, Alexander Perl, MD, Alison Loren, MD, Steven Goldstein, MD, Patricia Mangan, CRNP, Robert Sachs, Donald Seigel, MD, David Porter, MD

Blood (2004) 104 (11): 1872.

https://doi.org/10.1182/blood.V104.11.1872.1872

Published: 2004

Journal Articles

Pegfilgrastim Versus Filgrastim To Accelerate Hematopoietic Recovery after High Dose Melphalan and Autologous Hematopoietic Stem Cell Transplant (ASCT) for Multiple Myeloma.

Rebecca L. Olin, MD, Selina M. Luger, MD, David L. Porter, MD, Stephen J. Schuster, MD, Donald Tsai, MD, Phd, Sunita Nasta, MD, Alexander Perl, MD, Alison W. Loren, MD, Steven Goldstein, MD, Patricia Mangan, CRNP, Vicki Sherry, CRNP, Kathleen Cunningham, RN, Bob Sachs, Kim Hummel, Edward A. Stadtmauer, MD

Blood (2004) 104 (11): 5193.

https://doi.org/10.1182/blood.V104.11.5193.5193

Published: 2004

Journal Articles

Enhancing Graft-vs-Tumor (GVT) Activity of Donor Leukocyte Infusions by Ex-Vivo Expansion and Activation with CD3/CD28 Co-Stimulation.

David Porter, MD, Bruce Levine, PhD, Nancy Bunin, MD, Edward Stadtmauer, MD, Selina Luger, MD, Steven Goldstein, MD, Stephen Schuster, MD, Donald Tsai, MD, Sunita Nasta, MD, Alison Loren, MD, Alexander Perl, MD, Julie Oliver, CRNP, Ambika Sohal, Liz Veloso, RN, Stephen Emerson, MD, PhD, Carl June, MD

Blood (2004) 104 (11): 1640.

https://doi.org/10.1182/blood.V104.11.1640.1640

Published: 2004

NARROW

A Feasibility Study of Rapamycin with Hyper-CVAD Chemotherapy in Adults with Acute Lymphoblastic Leukemia (ALL) and Other Aggressive Lymphoid Malignancies and Evaluation of mTOR Signaling Using Phosphoflow

Reduced Intensity Conditioning with Fludarabine/Busulfan 6.4mg/Kg Results In High Donor Chimerism and Low Toxicity In Both Related and Unrelated Allo-SCT for Hematologic Malignancies.

Outcomes of Myeloablative Hematopoietic Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia with Relapsed or Refractory Disease

Combination Daclizumab and Infliximab for Steroid Refractory Acute Graft-Versus-Host Disease.

First Report of the Prophylactic Administration of Ex Vivo Co-Stimulated Donor Lymphocyte Infusion (DLI) from Related and Unrelated Donors after Reduced Intensity Conditioning for High Risk Hematologic Malignancies

A Robust Xenotransplantation Model for Acute Myeloid Leukemia

A Phase II Trial of Bexarotene, a Retinoid X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia

Phosphoproteomic Analysis of Primary Acute Myeloid Leukemia Cells Reveals Redundant Roles for Src Family Kinases in AML Survival

A Phase I Trial of Bexarotene, a Retinoid X Receptor Agonist, in non-M3 Acute Myeloid Leukemia: Evidence of Myeloid Differentiation and Clinical Activity.

A Randomized, Open-Label Study of Lestaurtinib (CEP-701), an Oral FLT3 Inhibitor, Administered in Sequence with Chemotherapy in Patients with Relapsed AML Harboring FLT3 Activating Mutations: Clinical Response Correlates with Successful FLT3 Inhibition.

Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy for Relapsed Multiple Myeloma.

Thalidomide and Dexamethasone Induction Therapy Is Associated with Superior Progression-Free Survival after Autotransplant for Myeloma.

Non-Myeloablative Conditioning with Allogeneic Progenitor Cell Transplantation for Relapsed Hodgkin’s Lymphoma: High Response Rate Despite Prior Chemoresistance.

Utility of Prophylactic Autologous Stem Cell Collection for Patients with Acute Myeloid Leukemia in First Remission.

Pegfilgrastim Versus Filgrastim To Accelerate Hematopoietic Recovery after High Dose Melphalan and Autologous Hematopoietic Stem Cell Transplant (ASCT) for Multiple Myeloma.

Enhancing Graft-vs-Tumor (GVT) Activity of Donor Leukocyte Infusions by Ex-Vivo Expansion and Activation with CD3/CD28 Co-Stimulation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only